Search

Your search keyword '"Allegre, T"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Allegre, T" Remove constraint Author: "Allegre, T"
45 results on '"Allegre, T"'

Search Results

1. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

2. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

3. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

4. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

5. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

6. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

7. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

9. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

10. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

11. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

12. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

13. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

14. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

15. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

16. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

17. Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment

18. SAT-149 - Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study

20. 324 HEV SERO-VIROLOGICAL PREVALENCE IN HIV-INFECTED PATIENTS IN FRANCE: A SOUTH–NORTH GEOGRAPHIC COMPARISON

26. Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals

27. Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial

28. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

29. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

30. A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients

31. Complete remission of long term duration of pulmonary Kaposi's sarcoma treated with interferon and bleomycine

35. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.

36. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.

37. Factors associated with social deprivation among older persons living with HIV.

38. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.

39. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.

40. Employment loss following HIV infection in the era of highly active antiretroviral therapies.

41. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

42. [Interferon alpha and pamidronate: a useful combination in the treatment of osteoporosis and systemic mastocytosis].

43. IL-6 and b-FGF overproductions precede development of AIDS-associated Kaposi's sarcoma.

44. [Hematologic manifestations in Campylobacter coli septicemia. Apropos of a case].

Catalog

Books, media, physical & digital resources